The Expanding Role of Somatostatin Analogs in Gastroenteropancreatic and Lung Neuroendocrine Tumors

被引:39
作者
Cives, Mauro [1 ]
Strosberg, Jonathan [1 ]
机构
[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Gastrointestinal Oncol, Tampa, FL 33612 USA
关键词
MALIGNANT CARCINOID-SYNDROME; CANCER STAGING CLASSIFICATION; AMERICAN JOINT COMMITTEE; HIGH-DOSE TREATMENT; RECEPTOR TYPES 1-5; OCTREOTIDE LAR; DEPENDENT REGULATION; PROGNOSTIC VALIDITY; PASIREOTIDE SOM230; LANREOTIDE;
D O I
10.1007/s40265-015-0397-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Somatostatin analogs (SSAs) were initially developed as antisecretory agents used for the control of hormonal syndromes associated with neuroendocrine tumors (NETs). In recent years, accumulating evidence has also supported their role as antiproliferative agents in well or moderately differentiated NETs. The phase III PROMID trial demonstrated that octreotide long-acting repeatable (LAR) can significantly prolong time to progression among patients with metastatic midgut NETs. More recently, the randomized CLARINET trial reported a significant improvement in progression-free survival in a heterogeneous population of patients with gastroenteropancreatic (GEP)-NETs treated with depot lanreotide. Octreotide and lanreotide target somatostatin receptor subtypes in a similar fashion, and appear to be clinically interchangeable; however, comparative noninferiority trials have not been performed. Further studies are needed to evaluate the efficacy of novel SSAs such as pasireotide in the refractory setting, and the role of high-dose SSAs for symptom and tumor control.
引用
收藏
页码:847 / 858
页数:12
相关论文
共 105 条
[61]  
O'Toole D, 2000, CANCER, V88, P770, DOI 10.1002/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO
[62]  
2-0
[63]  
Obemdorfer S., 1907, FRANKFURT Z PATHOL, P425
[64]   Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system [J].
Öberg, K ;
Kvols, L ;
Caplin, M ;
Delle Fave, G ;
de Herder, W ;
Rindi, G ;
Ruszniewski, P ;
Woltering, EA ;
Wiedenmann, B .
ANNALS OF ONCOLOGY, 2004, 15 (06) :966-973
[65]   Role of Somatostatins in Gastroenteropancreatic Neuroendocrine Tumor Development and Therapy [J].
Oberg, Kjell E. ;
Reubi, Jean-Claude ;
Kwekkeboom, Dik J. ;
Krenning, Eric P. .
GASTROENTEROLOGY, 2010, 139 (03) :742-U79
[66]  
ODORISIO TM, 1988, ANN NY ACAD SCI, V527, P528
[67]   Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors -: A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis [J].
Papotti, M ;
Bongiovanni, M ;
Volante, M ;
Allìa, E ;
Landolfi, S ;
Helboe, L ;
Schindler, M ;
Cole, SL ;
Bussolati, G .
VIRCHOWS ARCHIV, 2002, 440 (05) :461-475
[68]   Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study [J].
Pavel, Marianne E. ;
Hainsworth, John D. ;
Baudin, Eric ;
Peeters, Marc ;
Hoersch, Dieter ;
Klimovsky, Judith ;
Lebwohl, David ;
Jehl, Valentine ;
Wolin, Edward M. ;
Oberg, Kjell ;
Van Cutsem, Eric ;
Yao, James C. .
LANCET, 2011, 378 (9808) :2005-2012
[69]   DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4-and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours [J].
Ploeckinger, U. ;
Hoffmann, U. ;
Geese, M. ;
Lupp, A. ;
Buchfelder, M. ;
Flitsch, J. ;
Vajkoczy, P. ;
Jakob, W. ;
Saeger, W. ;
Schulz, S. ;
Dohrmann, C. .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2012, 166 (02) :223-234
[70]   Antitumor effects of somatostatin [J].
Pyronnet, Stephane ;
Bousquet, Corinne ;
Najib, Souad ;
Azar, Rania ;
Laklai, Hanane ;
Susini, Christiane .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2008, 286 (1-2) :230-237